Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics Global Limited (NASDAQ: PRE) announced its fourth quarter and full year 2022 financial results, reporting a revenue of US$275.8 million for 2022 and US$52.3 million for Q4 2022, reflecting a 19.2% decrease year-over-year. The Company achieved an adjusted EBITDA of US$58.3 million for 2022. Notably, Prenetics is shifting focus to precision oncology, highlighted by the acquisition of ACT Genomics, the first Asian firm to receive FDA clearance for its genomic profiling test. The Company aims to implement a US$20 million share buy-back program while also reducing its workforce by 60% to streamline operations and cut costs.
Prenetics Global Limited (NASDAQ: PRE) has announced the formation of a new Scientific Advisory Board (SAB) aimed at enhancing its diagnostic cancer genomics platform. The SAB comprises respected experts in oncology and genomics, including Prof. Tony Mok, who will chair the board. This strategic move is designed to leverage their expertise for advancing precision oncology, particularly early cancer detection. CEO Danny Yeung emphasized the significance of these appointments in driving innovative solutions for cancer treatment. Prenetics continues to focus on its goal of transforming patient care through advanced genomic technologies.
Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14 to 16, 2023. Founded in 2014, Prenetics aims to decentralize healthcare by making consumer health, clinical care, and medical genomics accessible worldwide. The company operates in nine locations, including the UK, Hong Kong, and India, and offers services such as genetic testing, colorectal cancer screening, and COVID-19 testing. The event underscores Prenetics' commitment to innovation in health and diagnostics.
F.N.B. Corporation (NYSE: FNB) has declared a quarterly cash dividend of $18.13 per share on its Non-Cumulative Perpetual Preferred Stock, Series E (NYSE: FNB.PRE). This dividend is equivalent to $0.45325 per depositary share. The payment will be made on February 15, 2023, to shareholders recorded as of January 31, 2023. With total assets nearing $43 billion and approximately 340 banking offices, FNB operates in several states and D.C., offering comprehensive commercial and consumer banking solutions.
Prenetics Global Limited (NASDAQ: PRE) announced a leadership change with Dr. Bayju Thakar appointed as CEO of Prenetics EMEA, effective immediately. This strategic move is aimed at enhancing the company’s growth in the complex EMEA healthcare market. Dr. Thakar, former CEO of Doctor Care Anywhere, brings over 20 years of healthcare experience and a strong digital health background. With an emphasis on expanding into primary care, IVF, and personalized cancer diagnostics, Prenetics seeks to leverage its robust balance sheet for both organic and inorganic growth opportunities across the region.
Prenetics has acquired a majority stake in ACT Genomics, enhancing its entry into the $80+ billion precision oncology market. ACT Genomics received FDA clearance for its ACTOnco genomic profiling test, the first of its kind from an Asia-based company. This comprehensive test analyzes 440 cancer-related genes to guide therapy decisions for solid tumors, potentially transforming cancer care in Asia. The FDA authorization may lead to insurance coverage and further R&D investment by Prenetics, reflecting a commitment to personalized medicine.
Prenetics Global Limited (NASDAQ: PRE) announced the acquisition of a majority stake in ACT Genomics Holdings for $20 million and 19.9 million shares. This strategic purchase integrates germline and somatic testing, enhancing Prenetics' offerings in the rapidly growing US$80 billion precision oncology market. ACT is expected to contribute US$25-30 million in revenue for 2023, solidifying Prenetics' position in cancer diagnostics. The acquisition is set to complete by December 30, 2022, pending usual conditions.
On November 30, 2022, Prenetics Global Limited (NASDAQ: PRE) announced a $20 million share repurchase program authorized by its board, effective over the next 24 months. This strategic move aims to enhance shareholder value amidst recent stock volatility. Additionally, Prenetics will be included in the MSCI Global Micro Cap Index (Hong Kong), marking a significant milestone. The company expects FY2022 revenues between $270-280 million and adjusted EBITDA of $47-53 million, demonstrating strong financial fundamentals and a robust balance sheet with $250 million in net current assets.
Prenetics Global Limited (NASDAQ: PRE) announced its Q3 2022 financial results, reporting revenues of US$80 million and a loss from operations of US$9 million. The company achieved an adjusted earnings of US$21 million and adjusted EBITDA of US$27 million with a gross margin of 59%. Prenetics ended the quarter with approximately US$250 million in cash. The company raised its full-year revenue guidance to US$270 million to US$280 million and adjusted EBITDA to US$47 million to US$53 million, reflecting strong growth and strategic expansion plans.
Prenetics Global Limited (NASDAQ: PRE) reported second-quarter revenue of US$51.7 million, with a loss from operations of US$(17.9) million. The company achieved an adjusted EBITDA of US$6.5 million and raised its full-year guidance for adjusted EBITDA to US$35 million to US$45 million, with revenue expectations set between US$255 million and US$275 million. The firm launched two new products and has a strong balance sheet with US$215.3 million in cash and equivalents as of June 30, 2022. Upcoming initiatives include a partnership to create a decentralized health data platform.